Organogenesis (ORGO) Stock Price, News & Analysis

Company Overview

Organogenesis Holdings Inc. is a biotechnology company that develops, manufactures and commercializes products intended to support tissue regeneration and wound healing. The company serves the advanced wound care and surgical and sports medicine markets, with a focus on therapies that help manage complex wounds and support the repair of damaged tissue.

Its product portfolio includes bioengineered skin substitutes and other biologic products, such as Apligraf, Dermagraft, NuShield, Affinity and NuCel. These products are used in clinical settings for applications including chronic and diabetic foot ulcers, venous leg ulcers, burns, surgical wounds and soft-tissue repair. Organogenesis also offers products used by surgeons and other healthcare professionals in reconstructive and regenerative procedures.

Founded in 1985, Organogenesis is headquartered in Canton, Massachusetts. The company primarily serves healthcare providers and institutions in the United States and has pursued international distribution for certain products. Its products are marketed through healthcare sales channels and are generally used under the direction of qualified medical professionals.

Key Stats

• Today's Range: $0.89 to $0.95
• 50-Day Range: $0.90 to $1.91
• 52-Week Range: $0.89 to $7.08
• Volume: 876,980 shs
• Average Volume: N/A
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $4.33
• Consensus Rating: Reduce

Organogenesis Stock Analysis - MarketRank™

Organogenesis scored higher than 53% of companies evaluated by MarketBeat, and ranked 750th out of 905 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.2 / 5
• Analyst Rating: Reduce

Consensus Rating

Organogenesis has received a consensus rating of Reduce. The company's average rating score is 1.67, and is based on no strong buy ratings, no buy ratings, 2 hold ratings, and 1 sell rating.

Upside Potential

Organogenesis has a consensus price target of $4.33, representing about 380.2% upside from its current price of $0.90.

Amount of Analyst Coverage

Organogenesis has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: N/A
• Proj. Earnings Growth: N/A

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

14.92% of the float of Organogenesis has been sold short.

Short Interest Ratio / Days to Cover

Organogenesis has a short interest ratio ("days to cover") of 21.16, which indicates bearish sentiment.

Change versus previous month

Short interest in Organogenesis has recently increased by 3.92%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Organogenesis does not currently pay a dividend.

Dividend Growth

Organogenesis does not have a long track record of dividend growth.

News and Social Media

• Score: 3.0 / 5
• News Sentiment: 0.82

News Sentiment

Organogenesis has a news sentiment score of 0.82. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.69 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Organogenesis this week, compared to 2 articles on an average week.

Search Interest

Only 4 people have searched for ORGO on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.

MarketBeat Follows

3 people have added Organogenesis to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days.

Company Ownership

• Score: 1.3 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Organogenesis insiders have not sold or bought any company stock.

Percentage Held by Insiders

18.80% of the stock of Organogenesis is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

49.57% of the stock of Organogenesis is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/06/2026
• Today: 10/27/2026
• Next Earnings (Estimated): 11/05/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:ORGO
• CIK: 1661181
• Web: organogenesis.com
• Phone: (781) 575-0775
• Fax: N/A
• Employees: 854
• Year Founded: 1985

Price Target and Rating

• Average Price Target for Organogenesis: $4.33
• High Price Target: $8.00
• Low Price Target: $2.00
• Potential Upside/Downside: +380.2%
• Consensus Rating: Reduce
• Rating Score (0-4): 1.67
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: 104,484,000
• Market Cap: N/A
• Optionable: Optionable
• Beta: N/A